

Amgen-Horizon Deal May Signal FTC's Return To Bargaining

BYLINE ARTICLES | LESS THAN 1 MIN READ


September 13, 2023

By: Laura C. Onken

On Sept. 1, just over a week before trial was slated to begin, the Federal Trade Commission and several states **agreed to settle** their challenge to Amgen Inc.'s proposed acquisition of Horizon Therapeutics, allowing the transaction to close.

[Click here to read the article.](#)

Related People



Laura C. Onken

Related Services

Antitrust

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Health Care Transactions Program 2025
SPONSORSHIP ANTITRUST
- Five Healthcare Antitrust Topics to Watch at the Upcoming Health Care Transactions Conference in Nashville
AXINN VIEWPOINTS ANTITRUST

- IAM Live: Auto IP USA 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved